OmniAb (OABI) Shares Outstanding (Diluted Average) (2021 - 2026)
OmniAb (OABI) reported Shares Outstanding (Diluted Average) of $128.2 million for Q1 2026, up 21.42% year-over-year from $105.6 million in Q1 2025, and up 12.86% quarter-over-quarter from $113.6 million in Q4 2025.
OmniAb (OABI) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $128.2 million in Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $128.2 million, up 21.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $128.2 million (up 21.42% YoY), and the FY2025 annual result was $113.6 million, up 11.01% from the prior year.
- Shares Outstanding (Diluted Average) rose to $128.2 million in Q1 2026 per OABI's latest filing, from $113.6 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $128.2 million in Q1 2026 and troughed at $82.6 million in Q1 2022.
- A 5-year average of $100.0 million and a median of $100.8 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) jumped 1552.24% in 2022, then climbed 1.61% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $85.3 million in 2022, then climbed by 16.84% to $99.7 million in 2023, then increased by 2.69% to $102.4 million in 2024, then rose by 11.01% to $113.6 million in 2025, then increased by 12.86% to $128.2 million in 2026.
- Business Quant data shows OABI's Shares Outstanding (Diluted Average) at $128.2 million in Q1 2026, $113.6 million in Q4 2025, and $108.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 128.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 128.25 Mn |
| Dec 31, 2025 | 113.64 Mn |
| Sep 30, 2025 | 108.87 Mn |
| Jun 30, 2025 | 105.89 Mn |
| Mar 31, 2025 | 105.62 Mn |
| Dec 31, 2024 | 102.37 Mn |
| Sep 30, 2024 | 102.39 Mn |
| Jun 30, 2024 | 101.46 Mn |
| Mar 31, 2024 | 100.76 Mn |
| Dec 31, 2023 | 99.68 Mn |
| Sep 30, 2023 | 99.91 Mn |
| Jun 30, 2023 | 99.33 Mn |
| Mar 31, 2023 | 99.16 Mn |
| Dec 31, 2022 | 85.32 Mn |
| Sep 30, 2022 | 82.61 Mn |
| Jun 30, 2022 | 82.61 Mn |
| Mar 31, 2022 | 82.61 Mn |
| Dec 31, 2021 | 82.61 Mn |
| Sep 30, 2021 | 5.40 Mn |
| Jun 30, 2021 | 5.00 Mn |